<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631603</url>
  </required_header>
  <id_info>
    <org_study_id>StopEAA</org_study_id>
    <nct_id>NCT02631603</nct_id>
  </id_info>
  <brief_title>Stop Exogenous Allergic Alveolitis (EAA) in Childhood</brief_title>
  <acronym>chILD-EU_EAA</acronym>
  <official_title>Stop Exogenous Allergic Alveolitis (EAA) in Childhood: Healthy Into Adulthood - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prednisolone Treatment and Course of Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthias Griese</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stop exogenous allergic alveolitis (EAA) in childhood: healthy into adulthood - a randomized,
      double-blind, placebo-controlled, parallel-group study to evaluate prednisolone treatment and
      course of disease.

      The hypothesis of the study is that the treatment with placebo will not be inferior in terms
      of Forced Vital Capacity (FVC) improvement than treatment with systemic steroids after 6
      months treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be allocated to the two treatments, i.e., oral prednisolone and Placebo.

      Experimental intervention: Placebo Control intervention: Prednisolone Duration of
      intervention per patient: 3 months Follow-up per patient: 3 months

      Primary Objective:

      To evaluate outcome of EAA at 6 months and compare the medium term treatment with systemic
      steroids or Placebo.

      Secondary Objectives:

      To evaluate the completeness and knowledge of standardized and pedantic allergen elimination
      in families with a child with EAA.

      To evaluate the treatment of EAA with systemic steroids compared to placebo at 3 months.

      To evaluate the safety of the treatment of EAA with outpatient usage of systemic steroids
      compared to Placebo.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    funding pending
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The relative change from baseline through month 6 compared to change from placebo for forced vital capacity (FVC).</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Each patient will be classified as a responder or non-responder. A patient is considered as a responder, if the FVC value after 6 months is more than or equal to 93% of the norm values tabulated by Quanjer PH., et al. 2013</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity (FVC)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desaturation with standardized exercise test for children</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg scale</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs of care in €</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight for height (%)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Calculated from current weight * 100 / weight median for height of subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open usage of rescue glucocorticosteroids (mg/kg/6 months)</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Allergic Alveolitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules of placebo will be taken for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral prednisolone, anticipated dose:
first month after steroid pulse 0.5 mg/kg bw/d, second month 0.25 mg/kg bw/d, and third month 0.125 mg/kg bw/d in a single morning dose.
Individual capsules will be prepared using rounded dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administer Placebo as anti-inflammatory</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Administer Prednisolone as anti-inflammatory</description>
    <arm_group_label>Prednisolone</arm_group_label>
    <other_name>Decortin H</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Newly or previously diagnosed but not appropriately treated EAA in children,
             adolescents and young adults, aged between 3 and 25 years. The diagnosis of EAA must
             be confirmed by independent review of the findings by an expert panel and must be
             based on the presence of at least 4 of the following findings:

               -  History of appropriate allergen exposure

               -  Restrictive lung function (FVC &lt; 80% predicted for age and FVC/FEV1 &lt; 1) testing,
                  if appropriate for age (usually &gt; 5 y)

               -  Positive serum precipitins for bird/fungus exposed to (other allergens have
                  rarely, if every been demonstrated in children)

               -  Lymphocytosis in BAL (&gt; 20% of cells are lymphocytes)

               -  HRCT showing the characteristic nodular, linear or reticular opacities, and
                  ground glass pattern with increased attenuation.

               -  Lung biopsy demonstrating lymphocytic alveolitis, bronchiolitis, and
                  non-caseating histiocytic granulomatas.

               -  Controlled allergen exposure followed by characteristic reaction, including
                  fever, coughing, restriction on lung function, hypoxemia/desaturation at rest or
                  with exercise

          2. Unchanged inhaled steroids if on; if off, no plans to introduce them in the following
             6 months

          3. Agreement to home visit by independent study physician

        Exclusion Criteria:

          1. Contraindication for usage systemic steroids

          2. Critically ill patients needing respiratory support

          3. Non-compliance with medical treatments and interventions

          4. Women with childbearing potential and not practicing a medically accepted
             contraception during the trial and a positive pregnancy test (serum or urine) before
             and at the end of the trial. Reliable contraception are systematic contraceptives
             (oral, implant, injection) and diaphragm or condoms with spermicide.

          5. Pregnancy and lactation.

          6. Participation in another trial for EAA during the last 4 weeks or not beyond the time
             of 4 half-lives of the medication used. In the unlikely event a subject is already in
             another clinical study but not for EAA, that study must be stopped and the subject may
             be treated according to this protocol; a latency time between the two studies does not
             appear reasonable, as acute intervention is necessary for EAA. Treatment may be best
             done in the frame work of this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Griese, Prof., MD</last_name>
    <role>Study Director</role>
    <affiliation>Pediatric Pneumology, Ludwig-Maximilians-University Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Meike Hengst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Pneumology, Ludwig-Maximilians University Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum der Universität München, Haunersches Kinderspital</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Pneumologie, Allergologie, Mukoviszidose</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig-Universität, Allgemeine Pädiatrie u. Neonatologie</name>
      <address>
        <city>Gießen</city>
        <state>Hessen</state>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Kinder- und Jugendmedizin der Ruhr-Universität Bochum im St. Josef-Hospital</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Essen, Pädiatrische Pneumologie</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik u. Poliklinik für Kinder- u. Jugendmedizin der Universität Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>September 30, 2017</last_update_submitted>
  <last_update_submitted_qc>September 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Matthias Griese</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alveolitis, Extrinsic Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

